Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation

Full text
Picanco-Castro, Virginia [1] ; Bonamino, Martin Hernan [2, 3] ; Ramos, Rodrigo Nalio [4, 5] ; Guerino-Cunha, Renato L. [6] ; Oliveira, Theo Gremen M. [4, 7] ; Rego, Eduardo M. [8]
Total Authors: 6
[1] Hosp Clin Fac Med Ribeirao Preto Univ Sao Paulo, Fundacao Hemoctr Ribeirao Preto, Ribeirao Preto, SP - Brazil
[2] Inst Nacl Canc INCA, Div Pesquisa Expt & Translac, Rio De Janeiro, RJ - Brazil
[3] Pesquisa & Colecoes Biol Fundacao Oswaldo Cruz VP, Rio De Janeiro, RJ - Brazil
[4] Fac Med Univ Sao Paulo HCFMUSP, Hosp Clin, Lab Invest Med Patogenese & Terapia Dirigida Onco, Sao Paulo, SP - Brazil
[5] Inst DOr Ensino & Pesquisa, Sao Paulo, SP - Brazil
[6] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Imagens Med Hematol & Oncol Clin, Ribeirao Preto, SP - Brazil
[7] Fundacao Pro Sangue Hemoctr Sao Paulo, Sao Paulo, SP - Brazil
[8] Hosp Clin Fac Med Ribeirao Preto HCFMRP USP, Ribeirao Preto, SP - Brazil
Total Affiliations: 8
Document type: Journal article
Source: Hematology, Transfusion and Cell Therapy; v. 43, n. 2, p. S54-S63, NOV 2021.
Web of Science Citations: 0

Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of these cell therapy products came after an extended period of preclinical evaluation that demonstrated unprecedented efficacy in this difficult-to-treat patient population. This review article outlines the main preclinical evaluations needed for CAR T cell product development. (C) 2021 Published by Elsevier Espana, S.L.U. on behalf of Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular. (AU)

FAPESP's process: 19/25309-0 - Off-the-shelf engineered NK cells for the treatment of Leukemia and Lymphoma treatment
Grantee:Virginia Picanço e Castro
Support Opportunities: Regular Research Grants
FAPESP's process: 20/07055-9 - Nucleus of Cellular Therapy - NuTeC
Grantee:Dimas Tadeu Covas
Support Opportunities: Research Grants - Problem-Oriented Research Centers in São Paulo
FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
Grantee:Dimas Tadeu Covas
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC